Bayer diagnostics unit joins Global Healthcare Exchange
Bayer HealthCare, Diagnostics Division, a part of the German Bayer group, has said that it has entered into an agreement with Global Healthcare Exchange, which offers an open and neutral electronic trading exchange to improve supply chain efficiencies. Through this agreement, Bayer Diagnostics aims to enhance the "buying experience" for its customers by streamlining the purchasing process and reducing costs.
With a comprehensive portfolio of diagnostics products for the central and physician office labs, Bayer Diagnostics will integrate into GHX's trading exchange, enabling it to connect to, and conduct business electronically with more than 2,000 hospitals and other health care providers. With this, the firm says its customers can improve transaction quality and processing time, while health care providers can increase both the types of products purchased and the percentage of their overall purchasing conducted electronically.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze